Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer

Vincent Chen, Eiji Iwama, In Kyu Kim, Giuseppe Giaccone

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences